CTICasesInfliximab-Induced Lymphoplasmacytic Infiltrate
Imaging findings
Chest radiographs and CT demonstrate widespread, bilateral, ground-glass opacities and areas of consolidation predominantly involving the lung bases. A subsequent biopsy demonstrates a benign, polyclonal lymphoplasmacytic infiltrate without malignant features, which completely cleared following drug cessation and a course of corticosteroid therapy.
Key takeaways
Anti-TNF agents such as infliximab can occasionally trigger a drug-induced pulmonary reaction characterized by a polyclonal lymphoplasmacytic infiltrate. This must be distinguished from malignant lymphoproliferative disorders or progressive infections, as management relies on withdrawing the offending biologic agent and administering systemic corticosteroids.
AI-assisted summary — may contain errors. Verify against the source video. Learn more
More from this webinar
- Thalassemia with Extramedullary HematopoiesisMetabolic
- Traumatic Aortic TransectionTrauma
- Pulmonary CoccidioidomycosisInfection
- Surfactant Protein C Mutation-Associated Pulmonary FibrosisILD
- Iatrogenic Aortic Injury from Intra-Aortic Balloon Pump (IABP)Iatrogenic
- Spontaneous Coronary Artery Dissection (SCAD)Vascular
- Post-Lobectomy Pulmonary Vein Stump ThrombusVascular
- Pulmonary ActinomycosisInfection
See all cases from August 13, 2021 →